Novartis

Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Fierce Pharma
Thu, 02/8/18 - 11:55 pm
Novartis
Kymriah
pricing
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Forbes
Thu, 02/8/18 - 11:47 pm
Novartis
drug pricing
Kymriah
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
Thu, 02/8/18 - 11:18 am
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
FDA rejects Novartis’ Advair generic, leaving GSK without rival
Drug Delivery Business News
Thu, 02/8/18 - 09:17 am
FDA
Novartis
Advair
generics
GSK
Sandoz
Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
Biopharma Dive
Thu, 02/1/18 - 09:45 pm
Pfizer
drug manufacturing
generics
Momenta Pharmaceuticals
Copaxone
Novartis
Joe Jiménez, Novartis outgoing CEO, describes group’s strategy
GoinPharma
Thu, 02/1/18 - 09:27 am
Joe Jimenez
Novartis
Pharma CEOs
Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics
Endpoints
Wed, 01/31/18 - 09:20 am
Novartis
dwarfism
infigratinib
BridgeBio
FDA approves Novartis-acquired Lutathera for certain gut cancers
Biopharma Dive
Mon, 01/29/18 - 03:21 pm
Novartis
FDA
Lutathera
Pharma gets a seat at the table at private dinner with Trump at Davos
Stat
Sat, 01/27/18 - 09:44 am
Donald Trump
pharma industry
Vas Narasimhan
Novartis
Werner Baumann
Bayer
Novartis scores a quick FDA OK for its new cancer drug Lutathera, picked up in $4B buyout
Endpoints
Fri, 01/26/18 - 05:25 pm
Novartis
Lutathera
FDA
neuroendocrine tumors
Novartis move signals further gene therapy resurgence
EP Vantage
Fri, 01/26/18 - 11:12 am
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Here is the salary of new Novartis CEO Vas Narasimhan
GoinPharma
Fri, 01/26/18 - 09:04 am
executive pay
Novartis
Vas Narasimhan
Spark licenses blindness gene therapy rights outside U.S. to Novartis
Yahoo/Reuters
Thu, 01/25/18 - 12:00 am
Spark Therapeutics
Novartis
Luxturna
gene therapy
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
NASDAQ.com
Wed, 01/24/18 - 08:10 pm
Novartis
earnings
Cosentyx
Entresto
Big day looming, Novartis’ new CEO Vas Narasimhan readies his jump into a marketing melee
Endpoints
Wed, 01/24/18 - 09:16 am
Novartis
Pharma CEOs
Vas Narasimhan
Joe Jimenez
Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.
Fierce Pharma
Mon, 01/22/18 - 05:41 pm
Novartis
Arzerra
Genmab
CLL
chronic lymphocytic leukemia
Novartis ties a new round of biosimilar development programs to a partnership deal with India’s Biocon
Endpoints
Thu, 01/18/18 - 10:35 pm
Novartis
Biocon
drug development
biosimilars
Novartis aims for US approval of Humira biosimilar
Biopharma Dive
Wed, 01/17/18 - 09:55 pm
Novartis
Humira
biosimilars
AbbVie
Sandoz
Novartis goes 2-0 against J&J in psoriasis
Biopharma Dive
Wed, 01/17/18 - 11:36 am
Novartis
JNJ
psoriasis
Cosentyx
Stelara
Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar
Yahoo/Zacks.com
Wed, 01/10/18 - 10:18 am
Novartis
psoriasis
Cosentyx
biosimilars
ankylosing spondylitis

Pages